Naproxcinod

Modify Date: 2024-01-09 22:58:43

Naproxcinod structure	Common Name	Naproxcinod
	CAS Number	163133-43-5	Molecular Weight	347.36200
	Density	1.213	Boiling Point	489.475ºC at 760 mmHg
	Molecular Formula	C₁₈H₂₁NO₆	Melting Point	N/A
	MSDS	N/A	Flash Point	193.208ºC

Use of Naproxcinod

Naproxcinod (Nitronaproxen) is the first in class of cyclooxygenase (COX)-inhibiting nitric oxide donators (CINODs). Naproxcinod shows analgesic and anti-inflammatory effects, it can be used for the research of osteoarthritis and inflammation[1][2][3].

Name	naproxcinod
Synonym	More Synonyms

Description	Naproxcinod (Nitronaproxen) is the first in class of cyclooxygenase (COX)-inhibiting nitric oxide donators (CINODs). Naproxcinod shows analgesic and anti-inflammatory effects, it can be used for the research of osteoarthritis and inflammation[1][2][3].
Related Catalog	Signaling Pathways >> Others >> Others Research Areas >> Inflammation/Immunology
In Vitro	Naproxcinod (1-30 μM; 15 min) concentration-dependently increases cGMP level up to 27-fold over basal level[1]. Naproxcinod (1-100 μM; 8 h) concentration-dependently increases HO-1 mRNA in endothelial cells[2]. Western Blot Analysis[2] Cell Line: Endothelial and gastric mucosal cell lines Concentration: 30-1000 μM Incubation Time: 8 and 24 hours Result: Increased HO-1 protein levels in endothelial and gastric mucosal cells and increased HO-1mRNA levels in endothelial cells.
In Vivo	Naproxcinod (0-41 mg/kg; p.o. once daily for 42 weeks) shows a significantly higher mean BW (7.3%) than vehicle group and improves skeletal and cardiac disease phenotype in the mouse model of DMD[3]. Animal Model: C57BL/10 mice with Duchenne muscular dystrophy (DMD)[3] Dosage: 0, 10, 21 and 41 mg/kg Administration: Oral gavage; 0-41 mg/kg once daily for 42 weeks Result: Significantly improved fraction shortening and ejection fraction, and reduced inflammation in vivo.
References	[1]. Berndt G, et al. A common pathway of nitric oxide release from AZD3582 and glyceryl trinitrate. Eur J Pharm Sci. 2004 Feb;21(2-3):331-5. [2]. Berndt G, et al. AZD3582 increases heme oxygenase-1 expression and antioxidant activity in vascular endothelial and gastric mucosal cells. Eur J Pharm Sci. 2005 Jun;25(2-3):229-35. [3]. Uaesoontrachoon K, et al. Long-term treatment with naproxcinod significantly improves skeletal and cardiac disease phenotype in the mdx mouse model of dystrophy. Hum Mol Genet. 2014 Jun 15;23(12):3239-49.

Density	1.213
Boiling Point	489.475ºC at 760 mmHg
Molecular Formula	C₁₈H₂₁NO₆
Molecular Weight	347.36200
Flash Point	193.208ºC
Exact Mass	347.13700
PSA	90.58000
LogP	4.00680

Precursor 9
CAS#:1198786-35-4 4-bromo-butyl (... CAS#:1395256-92-4 benzoic (S)-2-(... CAS#:22911-39-3 4-(Nitrooxy)but... CAS#:669692-75-5 butane-1,4-diol...
CAS#:22204-53-1 Naproxen CAS#:146563-40-8 4-bromobutyl nitrate CAS#:51091-84-0 (S)-(+)-Naproxe... CAS#:3457-91-8 Butanediol dini...
CAS#:26159-34-2 naproxen sodium
DownStream 0